Prohibits the sale of certain medical solution containers containing PVC, DEHP or unintentionally added DEHP.
This bill would amend New York’s Environmental Conservation Law to create a new title regulating medical solution containers and medical tubing. It defines key terms such as DEHP, PVC, ortho-phthalates, medical solution containers, and medical tubing, and then sets product restrictions for items used to deliver medicines, fluids, and nutrition in health care settings.
Beginning January 1, 2030, the bill would prohibit the manufacture, sale, or distribution in New York of medical solution containers made with PVC or intentionally added DEHP. Beginning January 1, 2033, the same prohibition would extend to medical tubing. The bill also bars manufacturers from substituting other ortho-phthalates for DEHP in revised or new products and sets a limit for unintentionally added DEHP at 0.1 percent by weight in covered products.
The bill would add a new product-safety restriction to New York environmental law affecting manufacturers, distributors, and sellers of medical packaging and tubing used in hospitals, outpatient facilities, and other health care settings. It would phase in compliance over time, first for medical solution containers and later for medical tubing, while also establishing a contamination threshold for unintended DEHP presence. The measure would likely require product reformulation, supply-chain changes, and compliance monitoring by affected businesses and health care product suppliers.
No committee transcript or vote record is provided, so there is no documented floor or committee debate to gauge sentiment. Based on the bill text alone, the measure appears to reflect a public-health and environmental safety approach aimed at reducing exposure to PVC and phthalates in medical products. The absence of recorded votes or discussion means support or opposition cannot be assessed from the supplied materials.
The main likely point of contention is the bill’s restriction on PVC and DEHP in medical solution containers and tubing, which could raise concerns about product availability, cost, manufacturing feasibility, and the adequacy of alternative materials. Another possible issue is the prohibition on replacing DEHP with other ortho-phthalates, which narrows reformulation options for manufacturers. The bill also sets a specific limit for unintentionally added DEHP, which may prompt debate over testing, enforcement, and what level of trace contamination is practical in medical supply chains.